Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Stock Short Interest Rises 5,382.3%

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) saw a large growth in short interest in September. As of September 15th, there was short interest totaling 451,633 shares, a growth of 5,382.3% from the August 31st total of 8,238 shares. Based on an average daily trading volume, of 4,671,517 shares, the days-to-cover ratio is currently 0.1 days. Approximately 163.6% of the shares of the company are short sold.

Scinai Immunotherapeutics Stock Performance

Shares of Scinai Immunotherapeutics stock traded down $0.12 on Thursday, hitting $1.86. 149,722 shares of the company’s stock were exchanged, compared to its average volume of 504,096. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.56. The stock has a market capitalization of $1.32 million, a PE ratio of -0.02 and a beta of 2.08. Scinai Immunotherapeutics has a 1 year low of $1.43 and a 1 year high of $16.30. The company has a 50-day simple moving average of $2.34 and a 200-day simple moving average of $4.04.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company is developing treatments designed to target disease-related immune pathways while potentially providing localized delivery and reduced systemic exposure.

Scinai’s development platform is based on NanoAbs, or nanobodies, which are small antibody-derived molecules intended to bind selectively to therapeutic targets.